John Park, MD

• Cheng-Yang Chang Endowed Professor of Pediatric Urology,
• University of Michigan Medical School
• Chief, Division of Pediatric Urology,
• C. S. Mott Children? Hospital, Ann Arbor, Michigan

This finding suggests that "psychological support" is an undefined response to a clinical need that requires specification antibiotics for uti in humans purchase augmentin 375 mg line. The remaining articles are organised around the following clinical domains: · Antenatal Screening (30% of articles): these articles show a well-organised response to the problem of introducing antenatal screening in an at-risk population pipistrel virus augmentin 375 mg purchase overnight delivery. They illustrate the complexity of creating a comprehensive solution that includes governmental support taking antibiotics for sinus infection while pregnant purchase genuine augmentin, legislation bacteria escherichia coli purchase 625 mg augmentin mastercard, community education bacteria reproduction process generic 625 mg augmentin free shipping, and faceto-face interaction. The efforts to replicate this success have yielded some articles that identify specific complications associated with community demographic diversity in migrant populations. Experience from antenatal screening that led to successful implementation were in relatively small and homogenous environments. The challenges when implementing clinical intervention within complex heterogeneous populations have not been fully considered however. Psychological problems (14% of articles): There appears to be a wide-ranging crossnational recognition that patients with thalassaemia are vulnerable to experiencing psychiatric problems (Cakaloz 2009, Saini 2007, Shaligram 2007a, Shaligram 2007b, Aydinok 2005, Pradhan 2003, Sadowski 2002). Social Support (20% of articles): these studies address the range of needs of families and patients. This domain appears to have the most interventional studies that include targeting changes in institutional organization practices (Marovic 2008), patient group sessions (Marovic 2008, Yamashita 1998), family therapy (Mazzone, 2009), and patient chelation camps (Treadwell 2001). As a whole this literature suggests that patients with thalassaemia and their caregivers are faced with many distinct psychological and social challenges which impact emotional functioning and may result in increased vulnerability for experiencing symptoms of psychiatric illnesses, such as depression and anxiety (Duman 2011, Gharaibeh 2009, Marovic 2008, Prasomsuk 2007, Roy 2007, Zafeiriou 2006, Aydinok 2005, Vardaki 2004, Galanello 2003, Angastiniotis 2002, Politis 1998, Ratip 1996, Ratip 1995). Psychological support appears to be loose reference to a broad mix of organizational responses to clinical needs, and not a coherent interventional strategy. They lack analytic rigor because standardised behavioral and social science research instruments were not used. Recent reports show an effort to develop the needed rigorous, scientific understanding of patient reported outcome within ongoing studies of iron chelation therapy (Haines 2013, Porter 2012,Trachtenberg 2012a, Trachtenberg 2012b, Porter 2011, Sobota, 2011, Trachtenberg 2011, Evangeli 2010). These efforts should establish the analytic foundation for future interventional studies in psychological support. Practical Considerations Recommendations for standards of care for psychological support require a practical organizational model. As the specific challenges associated with being a patient with thalassaemia differs throughout development, a clinical pathway model that starts with the functional landmarks that define the patient and family experience is helpful (diagnosis-treatment). Firstly, because thalassaemia is a chronic disease presenting shortly after birth, the natural growth from infant to adult will shape how patients learn to live with their disease. In the early stages, patients are dependent on their family caregivers, and as they develop, the patient must learn to successfully manage their own care. Pediatrics typically works with the patient and their family and adult medicine works with the individual patient. Systematic studies to examine different intervention modalities that may help patients and families effectively cope with the particular challenges inherent at each time point are needed. As most of the existing literature consists of descriptive reports and cross-sectional studies, the following practical recommendations are largely based on what we know from our clinical work and/or research with other chronic illnesses. Point of diagnosis Parents will undergo a series of changes after their child is diagnosed with thalassaemia (shock, denial, sadness/anger, adaptation, reorganization) (Drotar, 1975). One of their most important immediate concerns is getting reliable information (Starke, 2002). Learning the additional tasks associated with caring for a child with thalassaemia 213 can be overwhelming to the parent and lead to psychological distress (Politis, 1998; Galanello, 2003; Yamashita, 1998). Importantly, if parents feel overwhelmed with caring for their child, effective management of the illness may become compromised (Otsuki, 2010). To minimize these feelings, effective psychological support of parents around the time of diagnosis should include: · · · · Providing necessary information about thalassaemia. Occasions to meet parents of older children diagnosed with thalassaemia, as this can help increase social support and confidence, while decreasing feelings of helplessness and hopelessness. Access to psychosocial clinicians who can help them explore and manage their feelings of loss in a constructive manner. This is because parental behaviors and attitudes throughout development will lay the groundwork for how children will cope with their condition. Parents who demonstrate healthy coping and understand that a well-managed patient who adheres to his/her therapy can live a successful life (Pakbaz 2010) will help their children to learn to make thalassaemia a piece of who they are, rather than what defines them. Introducing the family to an appropriately experienced family with a child who has thalassaemia can be a helpful learning experience for parents of young children. Start of blood transfusion the best ways to provide psychological support aimed at helping children effectively cope with invasive medical procedures has been widely studied (Edwards 2010, Thompson 2009, Brown 2007, Hayman 2002, Brown, 1999, Hymovich, 1992). It is essential to help parents and children engage in effective coping strategies as soon as developmentally appropriate, as the experience of distress during a medical procedure has been found to be predictive of distress during future procedures (Frank 1995). Starting at a very young age, children often look to their parents for signals on how they should react in anxiety-provoking, novel situations. In one study, parent behavior during an invasive medical procedure accounted for 53% of the variance in child distress behavior (Frank 1995). Providing information about the procedure prior to the actual procedure and giving the parent a job to do. Specific coping strategies aimed directly at the child have been particularly useful in helping children cope effectively with invasive medical procedures. In a meta-analysis of psychological interventions for needle-related procedural distress in children and adolescents, distraction was found to be one of the most efficacious coping techniques (Uman 2008). In fact, a recent study conducted with patients with thalassaemia found that bubble blowing during an injection helped reduce anxiety (Bagherain 2012). As children get older, they may ask for more information about transfusions or other invasive medical procedures. Fostering trust, reducing uncertainty, correcting misconceptions, enhancing the belief in their ability to cope with a procedure, and minimizing distress are some of the potential benefits in providing advance information about a procedure to a child (Jaaniste 2007; Jipson 2007). Effective preprocedural information should include: · · A developmentally appropriate verbal explanation of what the child will see, hear, feel, and smell during, before, and after the procedure. Minimally threatening, but accurate information, as children who are given information that turns out not to be true. Where possible, medical play can help young children understand their therapeutic regimen (Burns-Nader 2012, Bandstra 2008, Bolig 1991, McCue 1988). For example, although oral chelators are associated with less distress and better quality of life in older patients, due to specific developmental characteristics of very young children. When starting chelation therapy, parents should be encouraged to develop consistent routines around medication taking. Behavioral interventions which include increased monitoring and incentives for meeting goals have been shown to be successful at improving adherence in patients with thalassaemia (Koch 1993). These may include verbal praise, stickers, or small toys or other incentives earned either immediately or over time, for cooperating with daily chelation. When this occurs, it is essential to identify why the patient is having difficulty following the prescribed plan. Interventions that do not consider the specific barrier to adherence will have limited success (see Table 1 for common barriers and suggested interventions). In general, effective interventions aimed at improving adherence usually: · · · · Incorporate behavioral or multiple strategies. Start from where the patient is at, gradually increasing goals, while working towards the ideal. Further, patients with thalassaemia may be vulnerable to experiencing cognitive deficits (Duman 2011, Nevruz 2007, Economou 2006, Zafeiriou 2006, Armstrong 2005, Lucke 2005, Zafeiriou 2004, Monastero 2000). If there are concerns from parents or the school, it may be valuable for patients to participate in neuropsychological testing to assess for any concerns and provide recommendations that could help support the patients learning potential. Adolescence and transition to increased self-care Adolescence is a time when adherence to daily medical regimens often declines (Trachtenberg 2011). Frequently the transition of responsibility from the parent to adolescent occurs before the patient is emotionally ready, resulting in poor adherence. Because adolescents are vulnerable to having their decision making being driven by their desire to be independent and to fit-in with peers, parents need to continue to play an active role in monitoring adolescents self-care. Shared responsibility between the patient and caregiver has been found to be associated with better adherence (Evangeli 2010, Treadwell 2001). Also, to avoid the negative consequences of abrupt shifts in responsibility, the transition of responsibility needs to: · · Occur gradually over time, starting when children are young. Teach older patients how to take over responsibility for often-overlooked tasks, such as ordering supplies and making medical appointments. Transition to adult Care One reason why adherence may be lowest in young adults (Trachtenberg 2011) is because of insufficient psychosocial support as patients transition from pediatric to adult medical providers. Often the transition to adult care providers happens in an abrupt manner, leaving the patient unprepared for the shift to adult medicine (Bryant 2009). Discussions about transitions should occur well in-advance of the actual transfer 217 in care and should include an exploration of the patients concerns and how they will prepare for and manage the changes inherent in moving from a pediatric to adult medicine clinic. Further, a well-coordinated transitional plan should be developed, which includes: · · Opportunities to orient the patient to an adult clinic and the adult care system. An emerging concern that is common in adult patients with thalassaemia is the experience of pain (Haines 2013, Trachtenberg 2010). The presence of pain in the non-thalassaemia adults is associated with decreased social function and increased depression (Ozminkowski 2012, Garber 2010, Avlund 2007, Dunn 2004, Koenig, 1997, Burckhardt 1985). Clinicians should encourage patients with pain to engage in a variety of empirically validated (Shega 2012, Palermo 2010, Eccleston 2009) cognitive and behavioral coping strategies which have been shown to successfully help patients manage their pain and distress through learning how to regulate their emotional and physical responses to pain. Meeting other patients and families with chronic medical conditions through attending camps, events sponsored by specific illness foundations, or one-to-one meeting facilitated by a clinician. This is best accomplished through a multidisciplinary team approach, which include nurses, social workers and psychologists who meet with the patient and families on a regular basis as part of their standard care. These clinicians are best suited to assess for any social, emotional, or cognitive concerns and intervene with additional support when necessary. Importantly, by including psychological support as part of standard care, some of the stigmatization associated with seeing a therapist may be removed. Summary and Recommendations Overall, despite a general lack of large scale, randomised, controlled trial evidence conducted with patients with thalassaemia, there are innumerable cohorts of casecontrolled analytic studies to suggest that psychological well-being impacts on adherence to treatment for chronic disease in general (B). In thalassaemia, the published reports to demonstrate this linkage are mainly descriptive studies (C). A meta-analysis would suggest that more recent efforts are more towards "B" grade investigations (usually ancillary studies attached to robust controlled trials in other clinical areas). However, the lack of uniform instruments and standardised measurements weakens this assessment. The findings to date suggest that: · · · · · Psychological well-being impacts on adherence to chelation treatment in Thalassaemia Major and hence on survival (C). Patients with thalassaemia are vulnerable to experiencing psychological challenges (C). Patient-reported health outcome shows that oral chelation therapy has a beneficial impact, relative to parenteral chelation (B). Neuropsychological investigation of cognitive deficits show that there are clear intellectual and psychopathological problems in a very limited number of thalassaemia patients (B). Benefits of psychological support have been suggested using a variety of approaches (C) which include: - targeting changes in institutional organization practices - patient group sessions - family therapy - patient chelation camps In all chronic illness, continuity of comprehensive care across the lifespan is essential for long-term, beneficial health outcome (A). Institutional organizational support for multidisciplinary teams is essential (A). There is a growing body of evidence that highlight the problems associated with transition from pediatric care to adult internal medicine in inherited chronic disease (B). Rare and neglected diseases complicate resource allocation models and lead to notable health disparities (A). In thalassaemia, these problems are known and reports from expert committees recommend addressing them, but there are no formal studies of the problems, much less any standardised evidence (F). Psychological support should be tailored to the patients age - Children (in general, A, thalassaemia C) - Adolescents ­ transition (in general, B, thalassaemia C) - Older adults ­pain issues (in general, A, thalassaemia C) 219 Funding for clinical psychological support services could be more widely achieved if well-designed, multi-centre, interventional studies using common standardised instruments were undertaken to evaluate the benefit of psychological support to treatment adherence. The use of established behavioral and social science approaches in such studies need to identify the active components of "psychological support" that are most applicable to patients with thalassaemia. Cultural beliefs and coping strategies related to childhood cancer: the perceptions of South Asian immigrant parents in Canada. The effect of distraction by bubble-making on the procedural anxiety of injection in Thalassemic school-age children in Kerman thalasemia center [Farsi]. The role of child life in pediatric pain management: A survey of child life specialists. Transition of the chronically ill youth with hemoglobinopathy to adult health care: an integrative review of the literature. The effects of medical play on reducing fear, anxiety, and procedure distress in school-aged children going to visit the doctor. Outreach strategies for Southeast Asian communities: experience, practice, and suggestions for approaching Southeast Asian immigrant and refugee communities to provide thalassemia education and trait testing. The adaptation of parents to the birth of an infant with a congenital malformation: a hypothetical model. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Parent and staff behavior, previous child medical experience, and maternal anxiety as they relate to child procedural distress and coping. Physical and mental health-related correlates of physical function in community dwelling older adults: a cross sectional study. Providing children with information about forthcoming medical procedures: A review and synthesis. Differences in psychosocial and health correlates of major and minor depression in medically ill older adults. The relationship between parent-reported social support and adherence to medical treatment in families of adolescents with Type 1 diabetes.

Drug interactions affecting felbamate clearance in children are similar to those in adults antibiotic resistance fda cheap 1000 mg augmentin with visa. Conversely bacteria of the stomach buy augmentin 625 mg fast delivery, valproic acid and older age were found to decrease felbamate clearance [32] antimicrobial chemotherapy cheap augmentin american express. In a study that assessed felbamate pharmacokinetics in 24 elderly (66­78 years) and 11 young (18­45 years) subjects antibiotic resistance over time purchase discount augmentin online, felbamate clearance after a single dose was found to be about 20% lower in the elderly than in the young (31 antibiotic cipro augmentin 1000 mg buy free shipping. Felbamate was also less well tolerated in elderly subjects than in young subjects, as shown by higher rates of adverse event reporting and dropouts when multiple doses were given. These results indicate that the elderly may require lower initial dosing and a slower dose titration. As would be expected from a drug 40­50% eliminated unchanged in the urine, persons with renal failure will need lower doses of felbamate, with urinary clearance representing only 9­22% of overall clearance in these patients [37]. In patients with creatinine clearance values between 5 and 10 mL/min, the apparent oral clearance of felbamate was half that found in healthy control subjects. The decreased clearance in elderly may likely be due to decreased renal elimination. Drug interactions the metabolism of felbamate is accelerated by concomitant treatment with phenytoin or carbamazepine, resulting in an increase in felbamate clearance by about 40­50% [19,38,39]. Conversely, valproic acid decreases felbamate clearance by up to about 20% [20,21,25]. Induction of carbamazepine metabolism by felbamate is responsible for a modest reduction (about 20%) in serum carbamazepine levels in patients started on add-on therapy with felbamate. On the other hand, mean carbamazepine-10,11-epoxide concentrations increased from 1. The effect was evident after the first week of treatment and reached a plateau in 2­4 weeks [45]. Enzyme induction is also probably responsible for a decrease in serum levels of steroid oral contraceptives in women co-medicated with felbamate [46]. However, the most common interactions described in humans with felbamate involve inhibition of the metabolism of co-administered drugs, with a consequent increase in their serum concentration. Felbamate significantly increases the concentrations of phenytoin, and phenytoin dose decreases of about 20% were needed in the first major study of felbamate as an add-on drug to maintain stable phenytoin concentrations [47,48,49]. Felbamate has been found to increase the serum concentrations of phenobarbital [50,51] and N-desmethylclobazam metabolically derived from clobazam [52]. In one study of 10 patients on valproic acid monotherapy, valproic acid levels increased by 18% in the presence of 1200 mg/day felbamate and by 31% with felbamate doses of 2400 mg/day [53]. Serum level monitoring In the initial double-blind study in patients with focal seizures, most serum levels of felbamate ranged between 20 and 45 µg/mL [47]. However, in post-marketing experience, concentrations between 40 and 100 mg/mL have been commonly found in persons responding favourably (Leppik, personal experience). In general, felbamate dosage can be individualized solely on the basis of clinical response. However, because there is a wide range of clearances for felbamate resulting from co-medication and other sources of individual variability, concentrations are not readily predictable from the doses, and measurement of blood levels can be useful to guide dosing. Felbamate 475 A review has suggested a reference range for felbamate concentrations of 30­60 mg/L [54]. It was stressed, however, that variability in response at these concentrations is considerable and that higher concentrations may confer additional benefit, though they are also associated with a higher probability of adverse effects [54]. Efficacy the first evidence that felbamate may be effective in humans came from a study of the pharmacokinetics of this drug [19]. The mean seizure frequencies during the 8-week analysis periods in the 56 patients completing the study were 34. Initial analysis showed no significant difference in seizure frequency between placebo and felbamate periods, but when a correction was made for the lower carbamazepine level noted during felbamate periods, the data suggested a significant antiseizure effect of felbamate [58]. Two blinded studies using felbamate in patients with partial seizures undergoing presurgical evaluation have been performed [55,59]. In a multicentre study, 64 subjects were randomized to receive felbamate (30) or placebo (34) after the presurgical evaluation had been completed. Patients were hospitalized for 8 days for observation and, if they remained in the study, they were discharged and followed as outpatients for an additional 21 days. In the felbamate group, 54% made it to the end of the observation period without a fourth seizure, whereas only 12% of the placebo group made it to this end-point (Kaplan­Meier analysis; P = 0. Both of these studies were proof of principle studies to demonstrate the effectiveness of felbamate in intractable patients. Additional open-label studies have demonstrated the effectiveness of felbamate in drug-refractory partial epilepsy [36,62]. In studies conducted before the discovery of serious hepatic and haematological toxicity, retention rate on felbamate in a clinical setting was favourable, as it was in a post-marketing study in which 91 of 132 refractory patients had enough clinical efficacy and lack of side-effects to warrant continuance of felbamate for 3 months or more after initiation [63]. The efficacy of felbamate in the treatment of Lennox­Gastaut syndrome was evaluated in a double-blind add-on parallel study involving 73 patients, mostly in the paediatric age range [57]. The dosage of felbamate was titrated to a maximum of 45 mg/kg of body weight per day or 3600 mg/day, whichever was less. Patients treated with felbamate had a 34% decrease in the frequency of atonic seizures (P = 0. The improvement that occurred in the double-blind study was sustained for at least 12 months in subsequent open-label follow-up studies [64]. Additional open-label studies have confirmed the effectiveness of felbamate in the Lennox­Gastaut syndrome [65]. In a retrospective study of mostly adult patients treated with felbamate for up to 20 years, the mean number of generalized tonic­clonic seizures per month was 6. In a study of various intractable paediatric epilepsy syndromes, a decrease in seizure frequency of 50% or more was seen in 63% after treatment with felbamate was initiated [67]. Studies of carcinogenicity after high doses demonstrated a statistically significant increase in hepatic cell adenomas in some rodents, and an increase in benign interstitial cell tumours of the testes in male rats [68]. No teratogenic effects have been found in reproductive or teratology studies in rats and rabbits [68]. No evidence for bone marrow or hepatic toxicity was observed in any of the preclinical studies. The most common adverse effects of felbamate as monotherapy were anorexia, vomiting, insomnia, nausea and headache. The most common adverse effects in polytherapy trials were anorexia, vomiting, insomnia, nausea, dizziness, somnolence and headache [70,71]. In data provided by Carter Wallace, in clinical testing 12% (120 of 977 adults) discontinued felbamate because of adverse effects. In order of increasing frequency greater than 1%, adverse effects leading to discontinuation included weight decrease (1. In studies with children, 6% (22 of 357) had felbamate discontinued, with symptoms leading to its discontinuance similar to those seen in adults. In one post-marketing use study, felbamate was initiated in 132 persons with chronic refractory epilepsy after its release. Three or more months after initiation, felbamate had been discontinued in 24 patients because of adverse effects. Gastrointestinal symptoms were the most common single reason given, and dermatitis occurred in four patients [63]. However, as felbamate came into wider use, reports of serious adverse events surfaced. As of May 1995, Carter Wallace had evidence of 31 domestic post-marketing reports of aplastic anaemia and 14 cases of hepatitis with eight deaths (Table 35. Of the cases reported, 23 (74%) met all of the criteria of the International Agranulocytosis and Aplastic Anemia Study [74]. Felbamate was judged to be the only cause in three cases, and the most likely cause in 11, for a total of 14 cases. Patient history and demographics suggest several features that may identify the high-risk patient. Only one paediatric patient (aged 18 years) was diagnosed with aplastic anaemia, and she had a prior diagnosis of systemic lupus erythematosus [75]. Duration of therapy prior to aplastic anaemia ranged from 23 to 339 days (mean 173 days) [75]. No cases reported up to the time of the review occurred in persons treated for more than 1 year, although in one additional case subsequently reported, the patient had been on felbamate for 8 years [76]. A total of 18 cases of hepatic failure were reported in patients receiving felbamate prior to September 1994. Evaluation of these reports indicates that 78% were female, 50% were aged 17 years or older and the mean time to presentation was 217 days (25­939 days). A panel of hepatologists met independently to review the data on these cases and concluded that only seven had a probable association with felbamate, whereas the others were complicated by status epilepticus, viral hepatitis, shock liver or acetaminophen toxicity [75]. Using all reported cases of hepatic failure, the estimated incidence would be 164 per million, but using the numerator of seven, the incidence of hepatic failure would be estimated at 64 per million, or a risk estimate for hepatic failure of 1 per 18 500­25 000 exposures. Statistics regarding valproic acid reported hepatic-related fatality estimates of 1 case in 10 000­49 000 for the combined population, and 1 in 500­800 cases in high-risk young children under the age of 2 years receiving valproic acid polypharmacy [77]. These data suggest that the hepatotoxicity associated with felbamate is in the general range seen with valproic acid [75]. However, the age range differs markedly, with felbamate safer in the paediatric population but worse in adults, with just the opposite for valproic acid. For both felbamate-induced aplastic anaemia and hepatotoxicity, females are at much greater risk (67% and 78%, respectively). Felbamate is excreted in the urine and one case of urolithiasis with a felbamate stone in a 15-year-old boy has been reported [78]. One case of crystalluria and renal failure in an intentional overdose case with serum felbamate concentrations of 200 mg/mL has been observed [79]. Toxic epidermal necrolysis after initiation of felbamate has also been reported [80]. The most up-to-date review on the felbamate literature is described in a 2006 expert panel consensus on the use of felbamate [74]. New exposures to felbamate are estimated at between 3200 and 4200 patients annually; over the past 10 years, approximately 35 000 patients have been started on felbamate. Since 1994, one case of aplastic anaemia has been reported, which was described in 2000 in a 42-year-old woman who had been taking felbamate for 8 years and had a prior history of melanoma. Felbamate was discontinued, thrombocytopenia resolved completely, but Felbamate 477 4 months later aplastic anaemia occurred, thought to be unrelated to felbamate. Two cases of liver failure (one in 1995 and one in 1996) have been reported in felbamate patients since 1994; one was related to status epilepticus and the other was thought to be secondary to felbamate use. Additional information has become available on the long-term effects of felbamate exposure. A prospective database affiliated with an epilepsy centre identified 77 long-term users of felbamate (data collected between 1986 and 2006) [36]. Laboratory and clinical outcomes are described in these patients, with an average treatment time of 7. The study demonstrated significant weight loss in the first year of felbamate use, but weight loss was not sustained over long-term use. Significant reductions were noted in generalized tonic­clonic seizures and simple partial seizures. No clinically significant changes in laboratory parameters pertinent to liver or bone marrow function were seen; these results support the concept that the most serious felbamate adverse reactions are idiosyncratic [36]. Patients considered unsuitable candidates for felbamate include patients with new-onset epilepsy and patients with a history of adverse haematological events, hepatic dysfunction, autoimmune disease or a strong family history of autoimmune disease. The expert panel concluded that felbamate appears to have a risk­benefit ratio that allows it to be used in selected patients with refractory epilepsy. A similar conclusion was reached in 1999 by a joint American Academy of Neurology and American Epilepsy Society practice advisory [68]. Dosing recommendations In adults, felbamate can be initiated at 1200 mg/day in three or four divided doses, with increases to 2400 and 3600 mg/day in weekly or biweekly increments of 600 or 1200 mg, as tolerated, as outpatients. A useful method to determine more precise doses for titrating patients is to start at approximately 20 mg/kg and increase to 40 mg/kg and then 50 mg/kg, 60 mg/kg or higher as needed. In children, recommended starting doses have been 15 mg/kg/ day with weekly incremental increases to 45 mg/kg/day. It may be expected that doses for children may be larger than those for adults, and in our experience we have used doses of up to 80 mg/kg. Felbamate is available as 400-mg tablets (scored, yellow, capsule shaped) useful for children; 600-mg tablets (peach-coloured, scored, capsule shaped) and suspension (600 mg/5 mL). It is not at all certain, however, that routine monitoring of haematological and hepatic parameters will be effective in detecting reactions. More important than laboratory testing is a careful review of the medical history and the avoidance of use of felbamate in patients who have a high-risk profile. Patients on felbamate should be taught the warning signs of aplastic anaemia and liver toxicity, and should have complete biochemistry and haematology tests performed whenever any of these appear. These signs and symptoms include severe lethargy, nausea and vomiting, flulike symptoms, easy bruising and unusual bleeding. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Simultaneous assay of felbamate plus carbamazepine, phenytoin, and their metabolites by liquid chromatography with mobile phase optimization. Determination of the anticonvulsant felbamate in beagle dog plasma by high-performance liquid chromatography. Determination of the anticonvulsant felbamate and its three metabolites in brain and heart tissue of rats. Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. Interaction of felbamate with several other antiepileptic drugs against seizures induced by maximal electroshock in mice. Interaction of felbamate and diazepam against maximal electroshock seizures and chemoconvulsants in mice.

The visual analogue scale test also did not show any statistically significant difference between the two groups infection quality control staff in a sterilization unit of a hospital cheap 625 mg augmentin with amex. In this analysis virus in children augmentin 1000 mg order with amex, which included a total of 720 patients exposed to rufinamide and 290 exposed to placebo antibiotics for sinus infection ceftin 625 mg augmentin purchase mastercard, 80 infection game plague inc augmentin 375 mg buy with mastercard. Headache bacteria and archaea similarities augmentin 625 mg for sale, dizziness, fatigue, nausea and somnolence were the most commonly reported adverse events [1]. The discontinuation rate resulting from adverse events in patients with focal epilepsy was 10% for the rufinamide groups and Table 47. Adverse events Any adverse event Headache Fatigue Nausea Somnolence Diplopia Tremor Blurred vision Nystagmus an bn Rufinamidea (%) 80. The most common causes for discontinuation in the rufinamide groups were dizziness, fatigue, headache, diplopia, nausea and ataxia. The rate of any adverse events and the most frequently reported adverse events increased as dosages were increased. Eleven of these were randomized, double-blind, placebo-controlled studies and 12 were open-label studies. The analysed population comprised children, adolescents and adults with focal epilepsy, generalized epilepsy or Lennox­ Gastaut syndrome. Short-term therapy safety data from double-blind studies included data on 1240 patients who received at least one dose of rufinamide and 635 who were on placebo. Sex distribution was similar: 620 males (50%) in the rufinamide group and 338 (53. In the double blind trials, the most common adverse events (rufinamide versus placebo group) in all age groups were headache (22. The percentage of rufinamide-treated patients experiencing serious adverse events was 6. Two deaths were reported in the rufinamide groups and four in the placebo groups [51]. During long-term therapy, common adverse events were similar to those observed during the short-term blinded studies. The majority of adverse events were mild to moderate in severity, and they typically occurred during the first 2 weeks of therapy. Rufinamide doses up to 7200 mg/day did not result in any significant symptoms of toxicity. The safety data in the children who participated in double-blind, placebo-controlled studies were also analyzed. The median age was 11 years, the median body weight was 36 kg and the median daily dose of rufinamide was 42. The significance of these findings are not clear as no signal for drug-induced sudden death or ventricular arrhythmia was reported. The T peak to T end interval did not show any statistically significant change when baseline and rufinamide period were compared. This findings can be considered anecdotal because in the double-blind studies rufinamide weight appeared to have no effect. Rash, urticaria, facial oedema, fever, elevated eosinophils, stuporous state and severe hepatitis were reported in a child on day 29 of rufinamide therapy, with resolution after discontinuation of the drug [52]. Based on information reported in the package insert, there have been additional possible cases of skin rash associated with at least one of the following: fever, altered liver function tests, haematuria and lymphadenopathy. Another case reported in detail was the occurrence of Stevens­Johnson syndrome in a 13-year-old girl with West syndrome [56]. The reaction developed 2 weeks after adding rufinamide to a treatment regimen that included valproic acid, clonazepam and levetiracetam. Effect on cognitive functions A positive cognitive profile of rufinamide was suggested by experimental studies in rodents indicating improvement in learning performance in the step-down passive avoidance paradigm, and ability to partially counteract electroshock-induced amnesia. Aldenkamp and Apherts [57] conducted neuropsychiatric testing in 189 patients with focal seizures (age range, 15­64 years) who received rufinamide 200, 400, 800 and 1600 mg/day as add-on treatment in a multicentre, double-blind, placebo-controlled, parallel-group study. The results did not reveal any statistically significant decline for patients taking any of the doses of rufinamide compared with baseline. Suggested maintenance dosages in Europe for the treatment of Lennox­Gastaut syndrome are 200­1000 mg/day 626 Chapter 47 (200­600 with valproic acid co-medication) for patients weighing less than 30 kg, and 400­1800 mg/day, 400­2400 mg/day and 400­3200 mg/day for patients weighing 30­50 kg, >50­70 kg and >70 kg, respectively [51]. Concerning other indications, a study in patients with primary generalized tonic­clonic seizures was negative, which might have been in part due to the low rufinamide dose tested (800 mg/day). Modest efficacy as add-on therapy has been demonstrated in adults with focal epilepsy. One monotherapy study was negative and one short-term monotherapy study was positive. Acknowledgement I am grateful to Lirit Franks, who assisted in the writing of this chapter. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. The influence of rufinamide on sodium currents and action potential firing in rodent neurons. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Rufinamide: clinical pharmacokinetics and concentration­response relationships in patients with epilepsy. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy. Pharmacokinetics and safety of ascending doses of adjunctive rufinamide in pediatric patients with inadequately controlled seizures. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox­Gastaut syndrome. In vitro transport assays of rufinamide, pregabalin and zonisamide by human P-glycoprotein. Serum concentrations of rufinamide in children and adults with epilepsy; influence of dose, age and co-medication. Population pharmacokinetics drug­ drug interaction analysis of rufinamide studies in patients with epilepsy. Dose­range relationships of rufinamide in patients with inadequately controlled partial seizures. Single center open label multiple dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women. Efficacy and safety of highversus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures. Efficacy and safety of rufinamide monotherapy for the treatment of patients with refractory partial seizures. Dose­response relationships of rufinamide in patients with inadequately controlled partial seizures. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo controlled trial. Randomized double-blind placebo-controlled parallel group study of rufinamide as adjunctive therapy for refractory partial onset seizures. Efficacy and safety of rufinamide as adjunctive therapy for inadequately controlled partial seizures in pediatric patients. Efficacy and safety of adjunctive rufinamide in patients with inadequately controlled primary generalized tonic­clonic seizures. Short term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox­Gastaut syndrome. Adjunctive rufinamide in Lennox­Gastaut syndrome: a long-term open label extension study. Epilepsy with myoclonic absences: favorable response to add-on rufinamide treatment in three cases. Treatment of malignant migrating partial epilepsy of infancy with rufinamide: report of five cases. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox­Gastaut syndrome. Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorder. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalized epilepsy. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Stiripentol inhibits the metabolism and increases the serum concentration of phenobarbital, carbamazepine, phenytoin, primidone, clobazam, N-desmethylclobazam and valproic acid There is insufficient information on the value of monitoring serum stiripentol levels Not clearly defined Drowsiness, ataxia, tremor, hypotonia, dystonia, hyperactivity, aggressiveness and other behaviour disorders, insomnia, nausea, anorexia, weight loss, vomiting and haematological abnormalities. Interactions with concomitant medications contribute to efficacy and adverse effects Well absorbed after oral administration 0. In children/adolescents with Dravet syndrome co-medicated with valproate and clobazam, mean half-life ranges from 8. Stiripentol follows Michaelis­Menten kinetics, and half-life increases with increasing serum concentrations Dose-dependent. In adults co-medicated with enzyme-inducers, apparent oral clearance decreased from 1. In children and adolescents with Dravet syndrome receiving stiripentol in combination with clobazam and valproate, mean apparent oral clearance averaged 0. Stiripentol has been developed during the last 30 years and used under a special programme in France and Canada for more than 15 years [3,4]. The actions of stiripentol are not blocked by antagonists of benzodiazepine or neurosteroid binding sites [2,11]. Chemistry Stiripentol (4,4-dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten3-ol) belongs to the family of aromatic allyl alcohols. Stiripentol is a chiral molecule with an asymmetric carbon atom at the 3 position [6]. Stiripentol is produced as a racemate, that is as a mixture of R(+)-stiripentol and S(-)-stiripentol in equal proportions. Pharmacology Stiripentol shows anticonvulsant effects in several acute experimental seizure models including the pentylenetetrazole, maximal electroshock, bicuculline and strychnine models [7,8]. Furthermore, stripentol is effective in an animal model of benzodiazepine-resistant status epilepticus induced by pilocarpine [9]. After repeated administration of the racemate to rats, a five- to six-fold increase in the S(­)-stiripentol: R(+)-stiripentol ratio was observed compared with the ratio found after a single dose [10]. This phenomenon may explain the observation that after chronic dosing in rats tolerance develops to its protective effects against pentylenetetrazole-induced seizures [8]. Published data on the pharmacokinetics of stiripentol in humans is mainly based on small series in adult healthy volunteers and adult patients with epilepsy. Very limited information is available on stiripentol pharmacokinetics in children. Stiripentol is rapidly absorbed, with peak serum concentrations being observed at 0. Bioequivalence between the capsules and the oral suspension (sachet) has been studied in healthy male volunteers after a 1000-mg single oral administration. Clinical supervision is recommended if switching between the capsule and the sachet formulations. Stiripentol should be taken with food because it degrades rapidly in an acidic environment, such as in gastric contents in a fasting state (for further details, see [14]). It should not be taken with milk, dairy products, carbonated drinks, fruit juices or food and drinks that contain caffeine or theophylline [14]. Stiripentol is highly (99%) bound to plasma proteins, and its distribution from the central compartment is slow, making the decline in serum concentration after a single dose multiphasic [15]. Stiripentol has non-linear Michaelis­Menten pharmacokinetics, presumably due to saturation of the enzyme systems responsible for the metabolism of the drug [15,16,17] and, as a result, dose increments produce disproportionately larger increments in serum concentration at steady state [15]. Stiripentol clearance also decreases during repeated dosing, presumably inhibiting the enzymes responsible for its metabolism [14]. Because stiripentol clearance is subject to enzyme induction, clearance values in patients not receiving enzyme inducing co-medication are much lower. A population pharmacokinetic study was conducted in 35 children and adolescents with Dravet syndrome treated with stiripentol concomitantly with valproate and clobazam [14]. In this study, clearance and volume of distribution of stiripentol were related to body weight by an allometric model with exponents of 0. As body weight increased from 10 to 60 kg, apparent oral clearance increased from 2. When adjusted for body weight, these values correspond to a decrease in body weight-adjusted apparent oral clearance from 0. As a result of a reduction in weight-adjusted clearance with increasing body weight, elimination half-life increased from 8. A paediatric pharmacokinetic study included 75 patients, 27% of whom were less than 6 years old, 21% were 6­11. This study confirmed that stiripentol has non-linear pharmacokinetics and that serum stiripentol concentrations increase more than proportionally with increasing dose. Compared with patients older than 12 years, dose-normalized serum stiripentol concentrations were 40% lower in children aged 6­12 years, and 58% lower in children aged less than 6 years. None of the metabolites detected in human blood displays pharmacological activity. Over 70% of the dose can be recovered in the urine as 13 different metabolites; a further 18% is recovered unchanged in the faeces [20].

Augmentin 1000 mg on-line. Healthcare-Associated Infections in the United States.

Physicians reviewed medical records to determine if there was a diagnostic error (defined as a missed opportunity to make or pursue the correct diagnosis when adequate data were available at the index [i antibiotic handbook order augmentin uk. The combined estimate of diagnostic error based on these three datasets was about 5 percent antibiotic ointment over the counter order augmentin 1000 mg online. Due to the definition of diagnostic error that Singh and colleagues employed antibiotics for persistent acne buy 1000 mg augmentin fast delivery, they asserted-as have other researchers-that this number may be a conservative estimate of the rate of outpatient diagnostic errors (Aleccia antibiotics for uti sulfa purchase augmentin mastercard, 2014) bacteria pseudomonas aeruginosa purchase augmentin 375 mg amex. Opportunities for improvement Medical records will continue to be an important source of data for assessing diagnostic errors. The advent of electronic forms that make some methods more cost-efficient, combined with mechanisms such as health information exchanges that may make it easier to assemble the entire patient diagnostic episode, may enhance the use of these methods. Developing a standard method that could be applied to a random sample of records (either nationally or in prespecified settings) would enhance opportunities to learn about both the incidence and the variation in the likelihood of patients experiencing a diagnostic error. Greater attention to the reliability with which the method is applied, particularly through the use of explicit rather than implicit methods, would also enhance the scientific strength of these studies. Medical Malpractice Claims Description of the data source Medical malpractice claims are defined as the electronic and paper databases maintained by professional liability insurers on claims that have been filed by patients or their families seeking compensation for alleged medical errors, including diagnostic errors; Copyright © National Academy of Sciences. It serves primarily as a system to facilitate comprehensive review of the credentials of clinicians, health care entities, providers, and suppliers, but it has been used for research as well. Many states also require claim reporting for purposes of maintaining a state-level database of paid claim information. Notes about the data source For a diagnostic error to be included in malpractice claims datasets, a patient must have filed a claim, which is a relatively rare event (Localio et al. For example, one study using data from the Harvard Medical Practice Study estimated that the probability of negligent injury was 0. The probability that a claim would be paid was 91 percent for negligent injury claims and 21 percent for nonnegligent injury claims. Thus, malpractice claims data provide a small window into the problem of diagnostic errors and are biased toward more serious diagnostic errors. For diagnosis-related claims, an average of 5 years elapses between the incident and the settlement of the claim (Tehrani et al. The validity of claims is uncertain; some claims will be filed and closed when no error occurred. A number of studies have assessed the validity of malpractice claims (Localio et al. Generally speaking, studies use only closed claims, that is, those for which the insurer has determined that no further legal action will be taken (claims may be closed due to settlement, Copyright © National Academy of Sciences. The researchers found that diagnostic errors were the leading type of paid malpractice claims (28. Diagnostic errors were almost twice as likely to be associated with patient death as other allegation categories (such as treatment, surgery, medication, or obstetrics claims). Almost 70 percent of diagnostic error claims were from the outpatient setting, but inpatient diagnostic error claims were more likely to be associated with patient death. The researchers estimated that the 2011 inflation-adjusted mean and median per claim payout for diagnostic error were $386,849 and $213,250, respectively. Schiff and colleagues (2013) reviewed closed primary care malpractice claims in Massachusetts from 2005 to 2009. During that 5-year period, 551 medical malpractice claims were from primary care practices. The diagnoses most often appearing in these claims were cancer, heart diseases, blood vessel diseases, infections, and stroke. It found that diagnostic errors are more common in the ambulatory care setting than in the inpatient or emergency department setting (56 percent versus 28 percent and 16 percent, respectively). In its analysis of diagnosis-related claims, the Doctors Company included information from 10 medical specialties (internal medicine, family medicine, obstetrics, cardiology, gynecology, general surgery, emergency medicine, orthopedics, pediatrics, and hospital medicine). For the 10 specialties, diagnosis-related claims constituted between 9 percent (obstetrics) and 61 percent (pediatrics) of total claims. Opportunities for improvement For malpractice claims to be useful for estimating the incidence of diagnostic error, it will be necessary to develop a better understanding of the underlying prevalence of diagnostic error as well as of the probability that a claim will be filed if an error has occurred and the likelihood that a filed claim will be settled. This will require significant research activity, and such research would have to explore variations by geography, specialty, type of error, and other factors. Health Insurance Claims Description of the data source the data source consists of electronic databases maintained by health insurance companies that contain the details of bills submitted by health care professionals and organizations for payment of services delivered. Typically, health care professionals and organizations bill multiple insurers for services. Notes about the data source For information to be present in the database, a patient has to have used a service, a claim must have been filed, Copyright © National Academy of Sciences. Because data are available electronically and represent the universe of claims filed for any insurer, the probability that a patient or episode of care has been selected for analysis can be calculated. Methods for identifying cases for review (denominator) Although a random sample of claims or groups of claims could be selected, it is more common to focus studies on those with patterns of care consistent with the possibility that a diagnostic error occurred. Similar databases provide the backbone for measuring process quality measures (such as 30-day rehospitalizations, appropriate assessment of left ventricular function in patients with congestive heart failure, and retinopathy screening among patients with diabetes). There are a few examples of the use of these data for investigating diagnostic error. Newman-Toker and colleagues (2014) identified patients who were admitted to the hospital with a diagnosis of stroke who in the previous 30 days had been treated and released from an emergency department for symptoms consistent with a stroke. The researchers note that their estimates of diagnostic error are inferred rather than confirmed because of the lack of clinical detail in health insurance claims. For example, analyses of claims data could be used in "look back" studies to identify the frequency with which acute coronary syndrome is misdiagnosed. Specifically, for those enrollees who are ultimately diagnosed with acute coronary syndrome, analysts could explore how frequently these beneficiaries were seen by health care professionals in the week prior to ultimate diagnosis (either in outpatient, emergency department, or hospital settings), the incorrect diagnoses that were made, and the factors associated with the diagnostic error. For instance, this epidemiologic approach using large administrative databases would make it possible to determine whether the diagnostic error occurs more frequently in specific hospitals, among specific types of clinicians or practice settings, or during particular days of the week when staffing is low or the volume of patients treated is unexpectedly high. The strength of this approach to understanding the epidemiology of diagnostic error is its ability to provide national estimates of diagnostic error rates across a vast array of conditions; to understand how these diagnostic error rates vary across geography and specific settings of care; to study the impact of specific care delivery models on diagnostic error rates. The main critique of this approach concerns the validity of the findings because of the limited availability of the clinical data necessary to confirm a diagnosis. Diagnostic Testing (Anatomic and Clinical Pathology) Description of the data source Diagnostic testing includes the examination of secretions, discharges, blood, or tissue using chemical, microscopic, immunologic, or pathologic methods for the purposes of making or ruling out a diagnosis. Analysis of the data may involve automated Copyright © National Academy of Sciences. Notes about the data source A unique feature of this type of data is that the original source data (the samples) are frequently available for reanalysis or inspection by another health care professional, thus allowing for an independent assessment based on the same data. A common taxonomy in this field distinguishes among five phases: pre-pre-analytic. For the purpose of examining the incidence of diagnostic error, the committee focused on those circumstances in which diagnostic testing results are a key information source. One study estimated that at least 10 percent of diagnoses require diagnostic testing results in order to be considered final; this number is likely higher today (Epner et al. Primary care clinicians order tests in about one-third of patient visits (Hickner et al. For anatomic pathology specimens, which require visual inspection and clinical judgment, second reviews by another pathologist offer insight into the potential rate of diag nostic error. Methods for identifying cases for review (denominator) Two methods-random samples and prespecified criteria-are commonly used to identify cases. For second review studies, an error is typically defined as a discrepancy between the findings of the first pathologist and the second pathologist. This review can identify errors in which a finding that leads to a diagnosis was missed and errors in which a finding was inaccurate. Second review studies typically assume that the second review is more accurate, but these studies do not typically link to patient outcomes. For other diagnostic tests, errors may be detected in the interpretation or communication of results in a timely manner. What is known Plebani reported that errors in laboratory medicine studies vary greatly because of the heterogeneity in study designs and the particular step or steps in the process that were examined (Plebani, 2010). A considerable focus on the analytic phase has led to substantial reductions in errors in that step; the pre- and post-analytic phases are seen as more vulnerable to error. A review published in 2002 (that only classified the diagnostic testing process in three phases) found that 32 to 75 percent of errors occurred in the pre-analytic phase, 13 to 32 percent in the analytic phase, and 9 to 31 percent in the post-analytic phase (Bonini et al. A study of urgent diagnostic testing orders in the hospital, which also classified the diagnostic testing process in three phases, found that 62 percent of errors were in the pre-analytic phase, 15 percent in the analytic phase, and 23 percent in the post-analytic phase (Carraro and Plebani, 2007). One study estimated that 8 percent of errors had the potential to result in serious patient harm (Goldschmidt and Lent, 1995). A systematic review of the literature on follow-up of test results in the hospital found failure rates of 1 to 23 percent in inpatients and 0 to 16. As Berner and Graber (2008) note, second reviews in anatomic pathology identify varying discrepancy rates. The College of American Pathologists and the Association of Directors of Anatomic and Surgical Pathology recently published guidelines based on a systematic review of the literature which found a median rate of major discrepancies in 5. The study also reported variations in the rate by the service performed (surgical pathology versus cytology), the organ system (single versus multiple), and the type of review (internal versus external). Kronz and Westra (2005) report a diagnostic discrepancy rate for the head and neck found by second review of between 1 and 53 percent for surgical pathology and 17 to 60 percent for cytopathology. A study by Gaudi and colleagues (2013) found that pathologists with dermatopathology fellowship training were more likely to disagree with preliminary diagnoses provided by nonspecialist pathologists. Opportunities for improvement the contribution of diagnostic testing to diagnosis is substantial, but it has not been systematically quantified recently. The understanding of this critical information source could be improved by developing better methods for identifying and enumerating Copyright © National Academy of Sciences. Additionally, studies that use diagnostic variance as a surrogate for accuracy (second reviews in which the second reviewer is considered more accurate) could benefit from the inclusion of patient outcomes. Medical Imaging Description of the data source the data are visual representations of the interior of the body generated using a variety of methods. In this context, the medical imaging data are reviewed by at least one other clinician, and the findings of all health care professionals are recorded. Notes about the data source As with anatomic pathology, a unique feature of this data type is the availability of the original images for review by a second radiologist. The focus is on those diagnoses for which medical imaging results are a key information source. Some studies have also involved radiologists conducting a second review of their own previously completed studies. What is known Berlin noted that medical imaging discrepancy rates as indicated by second review have not changed much over the past 60 years (Berlin, 2014). For instance, a study by Abujudeh and colleagues explored intra- and interobserver variability in medical imaging by having three Copyright © National Academy of Sciences. They found a major discrepancy rate of 26 percent for interobserver variability and 32 percent for intraobserver variability. Discrepancy rates were negatively associated with level of experience: the lower the level of experience of the preliminary reader, the more likely there was to be a discrepancy. In many of the second review studies in imaging, high error rates resulted from using a denominator that consisted only of abnormal cases. Studies that look at real-time errors-that is, devising an error rate using both normal and abnormal exams as the denominator-suggest an error rate in the 3 to 4. Opportunities for improvement Medical imaging plays a key role in many diagnoses, and errors in the use and interpretation of these studies can contribute to diagnostic error. For the purposes of estimating the incidence of diagnostic error due to errors related to medical imaging, it would be useful to identify the subset of diagnoses for which medical imaging results are central to making the diagnosis and to conduct studies to determine the likelihood of errors, the nature of those errors, and the variation in the circumstances under which errors occur. The role of second reviews in error recovery-identifying and "intercepting" errors before they affect patient outcomes-both for medical imaging and for anatomic pathology is discussed in Chapter 6. Notes about the data source As with all surveys, the results can be affected by a number of biases, including nonresponse bias (nonresponders being systematically different from responders, such as being more or less likely to have committed a diagnostic error) or reporting bias (systematic differences in the information that is revealed or suppressed, such as not reporting more serious errors). Unless the self-report can be compared to an authoritative source, it is difficult to determine the validity of rates based solely on self-report. Reports of survey findings have used different denominators, but often the denominator is the number of clinicians responding to the survey. Some studies have asked about errors known to the clinician that were made by other clinicians or experienced by family members. This approach makes estimating the incidence rate nearly impossible, as the true denominator is unknown. In their analysis of 583 reports of diagnostic error, they found that physicians readily recalled instances of diagnostic error; the most commonly reported diagnostic errors were pulmonary embolism, drug reactions, cancer, acute coronary syndrome, and stroke. Opportunities for improvement For the purposes of making national estimates of the incidence of diagnostic errors, it would be useful to have more clearly defined sampling frames, more detailed questions about the nature of the errors and the circumstances surrounding the error, and an opportunity to compare this method to other methods that use different data sources. Surveys have the advantage of being a potentially easy way to get a snapshot of diagnostic error rates, but the quality of the information may make this source less useful for other applications. The biases that are inherent in surveys are difficult to overcome and likely limit the utility of this source. Notes about the data source As with all surveys, the results can be affected by nonresponse bias and by reporting bias. Unless there are opportunities to compare answers to other data sources, it may not be possible to confirm the validity of the responses. Patient definitions of diagnostic errors might vary from the definitions of health care professionals. Patient surveys can be very useful in determining whether a new health problem was explained to the patients and whether they understood the explanation. Methods for identifying cases for review (denominator) Surveys are usually conducted on a sample of patients that is randomly drawn from some population.

References

• Ferry JA. The diversity of diffuse large B-cell lymphoma in extranodal sites: overview and update. J Hematopathol 2014;7(2):57-70.
• Khoury AE, Dave S, Peralta-Del Valle MH, et al: Severe bladder trabeculation obviates the need for bladder outlet procedures during augmentation cystoplasty in incontinent patients with neurogenic bladder, BJU Int 101:223n226, 2008.
• Serkin FB, Soderdahl DW, Hernandez J, et al. Combat urologic trauma in US military overseas contingency operations. J Trauma. 2010;69(Suppl 1):S175-S178.
• Orlov D, O'Farrell R, McCluskey SA, et al: The clinical utility of an index of global oxygenation for guiding red blood cell transfusion in cardiac surgery, Transfusion 49:682-688, 2009.
• Miles LA, Greengard JS, Griffin JH. A comparison of the abilities of plasma kallikrein, Beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. Thromb Res 1983;29:407-17.